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 ABSTRACT 
 Objectives  The genetic aetiology of osteoarthritis 
has not yet been elucidated. To enable a well-
powered genome-wide association study (GWAS) for 
osteoarthritis, the authors have formed the arcOGEN 
Consortium, a UK-wide collaborative effort aiming to scan 
genome-wide over 7500 osteoarthritis cases in a two-
stage genome-wide association scan. Here the authors 
report the fi ndings of the stage 1 interim analysis. 
 Methods  The authors have performed a genome-wide 
association scan for knee and hip osteoarthritis in 3177 
cases and 4894 population-based controls from the UK. 
Replication of promising signals was carried out in silico 
in fi ve further scans (44  449 individuals), and de novo in 
14  534 independent samples, all of European descent. 
 Results  None of the association signals the authors 
identifi ed reach genome-wide levels of statistical 
signifi cance, therefore stressing the need for 
corroboration in sample sets of a larger size. Application 
of analytical approaches to examine the allelic 
architecture of disease to the stage 1 genome-wide 
association scan data suggests that osteoarthritis is 
a highly polygenic disease with multiple risk variants 
conferring small effects. 
 Conclusions  Identifying loci conferring susceptibility to 
osteoarthritis will require large-scale sample sizes and 
well-defi ned phenotypes to minimise heterogeneity. 
 Osteoarthritis is the most common form of 
arthritis affecting 40% of people over the age 
of 70 years, and is associated with a substantial 
health economic burden. Osteoarthritis is thought 
to be caused by a complex interplay between 
environmental and genetic factors.  1  As with many 
common complex disorders, the genetic archi-
tecture of osteoarthritis has not yet been char-
acterised. Over the past decade, candidate gene 
association studies and genome-wide linkage 
scans have failed to identify robustly replicating 
osteoarthritis loci, with the notable exception 
of rs143383 in the  GDF5 gene.  2  A genome-wide 
association study (GWAS)  recently reported a sin-
gle novel locus associated with radiographically 
defi ned knee and/or hand osteoarthritis on chro-
mosome 7q22 (rs3815148 in the  COG5 gene),  3  
subsequently corroborated by a genome-wide 
association scan across four studies including the 
discovery set.  4  Both established that osteoarthri-
tis loci are represented by common variants (>0.2 
minor-allele frequency), have small effect sizes 
(allelic OR ~1.15), and reach genome-wide signifi -
cance (p<5×10 −8 ).  4    5  These associations have char-
acteristics typical of common complex traits and 
require large sample sizes for their detection. To 
enable a well-powered GWAS for osteoarthritis, 
we formed the arcOGEN Consortium, a UK-wide 
collaborative effort aiming to scan genome-wide 
over 7500 osteoarthritis cases in a two-stage 
genome-wide association scan. Here we report 
the fi ndings of our GWAS stage 1 analysis and 
replication studies, and describe the outcomes of 
statistical analyses designed to model the genetic 
architecture of osteoarthritis. 
 METHODS 
 An expanded description of the methods is pro-
vided in supplementary methods (available online 
only). The stage 1 genome-wide association scan 
included 3177 knee and/or hip osteoarthritis cases 
from the UK ascertained based on radiographic 
evidence of disease (Kellgren–Lawrence grade ≥2)  6  
or clinical evidence of disease to a level requiring 
joint replacement. Cases were genotyped using the 
Illumina Human610 platform (Illumina, San Diego, 
California, USA).  We used 4894  early-access publicly 
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the 65 independent signals (composed of 89 SNP) with p<10 −4 in 
all the osteoarthritis analysis, 17 are present with p<10 −4 in the 
hip osteoarthritis analysis and nine are present with p<10 −4 in 
the knee osteoarthritis analysis, but none reach p<10 −4 in both. 
 Additional analyses, including testing for pairwise interactions, 
examining overlap between genome-wide association scan and 
linkage scan signals, association with body mass index, devia-
tion from the additive model, genome-wide HapMap-based 
imputation, chromosome X association and genome-wide low 
frequency/rare variant analysis did not identify any additional 
osteoarthritis signals (supplementary methods; supplementary 
results, available online only). 
 The arcOGEN stage 1 GWAS is well powered to detect asso-
ciation with common variants of modest effect at the genome-
wide signifi cance level (eg, 90% power to detect an allelic OR of 
1.25 at a SNP with frequency 0.35). However, it is poorly pow-
ered to detect effects at the established osteoarthritis variants 
(8% and 4% power for  GDF5 and 7q22, respectively), as the 
index SNP (rs143383, risk allele frequency 0.67; rs3815148, risk 
allele frequency 0.23) both have small effect sizes (OR ~1.15).  2    3  
Retaining the arcOGEN case–control ratio of 1.54, 7774 cases 
would be required to achieve 80% power to detect an allelic OR 
of 1.15 at a SNP with risk allele frequency 0.67, and 9084 cases 
would be required to achieve the same power to detect the same 
effect size at a SNP with risk allele frequency 0.23. 
 To evaluate the robustness of association signals, we per-
formed sensitivity analyses using different control sets. We fi rst 
used ‘supercontrols’ (hip and knee osteoarthritis-free individuals) 
and found high correlation between association effect estimates 
(r=0.88) and 93% concordance in the direction of effects (sup-
plementary results, available online only). The two established 
osteoarthritis loci demonstrated stronger evidence for associa-
tion compared with the main analysis, even though the ‘super-
control’ sample size was smaller. We also used a subset of the 
population-based controls, genotyped on a different platform, to 
assess robustness to the typing method. We observed 100% con-
cordance in the direction of effect and high correlation between 
estimates of the OR (r=0.94) (supplementary results, available 
online only). Therefore, the choice of controls may have affected 
association strength but not the direction of effect. 
 The genetic architecture of osteoarthritis is likely to be poly-
genic with multiple variants along the spectrum of allele fre-
quencies contributing modest and small effects. Our polygene 
analyses support a model of osteoarthritis in which there is a 
substantial genetic component comprising multiple contributing 
variants with small effect sizes ( fi gure 1 ). SNP with p values as 
high as 0.25 appear to contribute to the genetic component of 
osteoarthritis (empirical p=3×10 −5 , based on ~85 million permu-
tations), with the bulk of the contribution seen in the 0–0.1 p 
value range (empirical p=3.5×10 −5 , ~101 million permutations). 
Evaluation of discreet p value bins corroborates this observation 
and supports a role for SNP with p values up to 0.25 (0.10>p>0.15 
bin empirical p=0.06; 0.15>p>0.20 bin p=0.0072; 0.20>p>0.25 
bin p=0.022), but with the major contribution coming from 
SNP with p<0.10 (0>p>0.05 bin p=3×10 −5 ; 0.05>p>0.10 bin 
p=0.0092). The estimated proportion of variance in disease state 
explained by the osteoarthritis score alleles is 3.05% (p=3.3×10 −4 
based on nine million permutations). This is in keeping with 
fi ndings in other complex common diseases.  7  
 DISCUSSION 
 Our stage 1 arcOGEN genome-wide association scan analysis 
results are in agreement with other large-scale genetic studies,  3    4  
available population-based UK controls from the Wellcome Trust 
Case Control Consortium 2 (WTCCC2) study, genotyped on the 
Illumina 1.2M Duo platform (Illumina).  We compared allele fre-
quencies across 514  898 autosomal single-nucleotide polymor-
phisms (SNP) passing quality control criteria. We also carried out 
joint-specifi c stratifi ed analyses (for hip and knee osteoarthritis). 
We carried out sensitivity analyses by comparing genome-wide 
case genotypes against different control sets (one overlapping 
but typed on a different platform and one non-overlapping set 
of osteoarthritis-free ‘supercontrols’). We took forward 102 
independent (r 2 <0.4) SNP with p<0.0001 to in-silico replication 
in three further osteoarthritis genome-wide association scan 
(from the deCODE, Framingham and Rotterdam studies) and a 
subset of 52 SNP in a UK-based genome-wide association scan 
(TwinsUK; supplementary table 1, available online only) (across 
4124 cases and 37  581 controls in total). Based on meta-analysis 
results across arcOGEN and these in-silico replication datasets 
(supplementary results, available online only), we prioritised 36 
SNP for de-novo replication in a further set of 6188 osteoarthritis 
cases and 8280 controls of European descent and for in-silico rep-
lication in 213 cases and 2531 controls from Estonia (supplemen-
tary table 1, available online only). To enhance our understanding 
of the genetic architecture of osteoarthritis, we applied analyti-
cal approaches  7  to stage 1 arcOGEN data to test the theory of 
polygenic inheritance. We used the arcOGEN stage 1 GWAS to 
derive a set of independent (r 2 <0.05) associated SNP (~62  000) 
from a subset of the data and then used this score allele set to 
evaluate the proportion of case–control status accounted for in 
the remaining samples. 
 RESULTS 
 In our stage 1 genome-wide association scan analysis, we 
observed a slight excess of associations compared with the null 
distribution (supplementary fi gure 2, available online only) and 
similar patterns of association for the joint and gender-stratifi ed 
analyses (supplementary results; supplementary fi gure 3, avail-
able online only). The genomic control infl ation factor λ was 
1.077, in keeping with other UK-based GWAS.  8  Although there 
was no signal exceeding genome-wide signifi cance (p<5×10 −8 ), 
89 SNP reached p values of less than 10 −4 (as opposed to 51 
expected under the null, binomial p=10 −6 ). 
 The strongest statistical evidence for association with 
osteoarthritis was obtained for rs4512391 on chr8 (OR for allele 
C 1.17; 95% CI 1.10 to 1.25; p=1.8×10 −6 ) approximately 66 kb 
upstream of the  TRIB1 gene. For knee osteoarthritis the most 
signifi cant fi nding was also observed at rs4512391 (OR for allele 
C 1.23, 95% CI 1.13 to 1.33; p=1.1×10 −6 ); for hip osteoarthritis, 
the strongest signal was rs4977469 (OR for allele A 1.30, 95% 
CI 1.17 to 1.45; p=1.2×10 −6 ), within intron 3 of the predicted 
 FAM154A gene (supplementary fi gure 1; supplementary fi gure 4; 
supplementary table 2, all available online only). Following rep-
lication studies in up to 58  917 independent European-ancestry 
samples, the overall statistical evidence for association was 
reduced, with the strongest signal for knee and/or hip osteoar-
thritis observed at rs2277831 on chr22 (OR for allele G 1.07, 
95% CI 1.1.04 to 1.11; combined p=2.3×10 −5 ), within intron 32 
of the  MICAL3 gene. For knee osteoarthritis the most signifi cant 
fi nding post-replication was observed at rs11280 (OR for allele 
C 1.10, 95% CI 1.05 to 1.16; p=3.2×10 −5 ), within  C6orf130 ; for 
hip osteoarthritis, the strongest signal was at rs2615977 (OR for 
allele A 1.10, 95% CI 1.05 to 1.15; p=1.1×10 −5 ) within intron 31 
of the  COL11A1 gene (supplementary fi gure 1; supplementary 
fi gure 4; supplementary table 2, all available online only). Out of 
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understanding of this genetic component, possibly leading to 
optimising treatment, developing effi cacious disease-modifying 
interventions, improving prognosis and tailoring intervention 
to the individual. 
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and clearly indicate that common SNP with large effect sizes are 
not likely to underpin the aetiology of osteoarthritis. The only 
two established osteoarthritis loci to date have small OR and 
our polygene analyses on common SNP suggest that the genetic 
architecture of osteoarthritis is likely to consist of numerous 
signals of similar magnitude. The signifi cant increase in sample 
size with stage 2 of the arcOGEN genome-wide association scan 
(~2.4 times as many cases) will increase the power to detect 
osteoarthritis associations. In addition, large-scale international 
meta-analysis efforts are underway and will ensure maximal 
GWAS sample size. A further important parameter in enhanc-
ing power and increasing the chances of success involves the 
improved defi nition of phenotype. One of the reasons why rep-
lication of fi ndings has been diffi cult to achieve in osteoarthritis 
could be the inherent heterogeneity of the different osteoarthri-
tis diagnostic and study inclusion criteria used. The fi eld is cur-
rently active in evaluating phenotype defi nition differences and 
their effects on study power.  4  
 The Wellcome Trust Case Control Consortium fi rst demon-
strated the utility of population-based, rather than disease-free, 
controls in GWAS.  8  Our ‘supercontrol’-based sensitivity analyses 
suggest that for a highly prevalent and heterogeneous disorder 
such as osteoarthritis, with multiple smaller effects contributing 
to overall susceptibility, the brute force approach of maximis-
ing sample size to balance misclassifi cation in controls is not as 
successful as it has been for other common diseases, in which 
‘low-hanging fruit’ discoveries (of loci with substantial effects) 
were robust to subtle allele frequency fl uctuations. 
 Osteoarthritis is a heterogeneous disease characterised by 
variable clinical features with conceivably different genetic 
aetiologies.  9  Although the allele score was associated with 
osteoarthritis, the proportion of disease variance explained can-
not be highly accurately quantifi ed, primarily because of signal 
attenuation (risk alleles are unlikely to be at the actual causal 
locus) and sampling variation. The genetic architecture of 
osteoarthritis is emerging as complex. Large-scale sample sizes 
and well-defi ned phenotypes will be required to gain a better 
 Figure 1  Summary of polygene analysis results evaluating the genetic architecture of osteoarthritis. Lines in red (real data) and blue (permuted 
data) show mean±1 SD of the Nagelkerke’s pseudo r 2 statistic, which indicates the proportion of case–control status accounted for by score alleles 
in the single-nucleotide polymorphism (SNP) sets. The blue line represents expectation under the null hypothesis of no genetic component to the 
disease. The red line represents stage 1 genome-wide association study data and shows that SNP at the tail of the p value distribution (up to p<0.25, 
but primarily p<0.10) have a signifi cantly higher case–control discriminatory capacity. 
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